Birchview Capital’s TG Therapeutics TGTX Stock Holding History

Birchview Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,000	Closed	-$285K	–	66
2021 Q4	$285K	Hold	15,000	–	–	0.18%	55
2021 Q3	$499K	Hold	15,000	–	–	0.34%	43
2021 Q2	$582K	Hold	15,000	–	–	0.35%	41
2021 Q1	$723K	Hold	15,000	–	–	0.43%	35
2020 Q4	$780K	Hold	15,000	–	–	0.45%	32
2020 Q3	$401K	Hold	15,000	–	–	0.27%	37
2020 Q2	$292K	Hold	15,000	–	–	0.18%	46
2020 Q1	$148K	Hold	15,000	–	–	0.13%	43
2019 Q4	$167K	Hold	15,000	–	–	0.12%	48
2019 Q3	$84K	Hold	15,000	–	–	0.06%	45
2019 Q2	$130K	Hold	15,000	–	–	0.08%	45
2019 Q1	$121K	Hold	15,000	–	–	0.08%	48
2018 Q4	$62K	Hold	15,000	–	–	0.06%	51
2018 Q3	$84K	Hold	15,000	–	–	0.05%	52
2018 Q2	$197K	Buy	+15,000	New	+$206K	0.13%	45

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Birchview Capital's TGTX Position: Q1 2022 in Review

Birchview Capital sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 15,000 shares — an estimated $285K sold.

Birchview Capital first reported a position in TGTX in Q2 2018 and held it in 15 quarters. The position peaked at $780K in Q4 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

Birchview Capital reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
Birchview Capital sold 15,000 TG Therapeutics shares in Q1 2022, an estimated $285K.
Birchview Capital first reported a position in TG Therapeutics in Q2 2018 and held it in 15 quarters.
Birchview Capital's TG Therapeutics position peaked at $780K in Q4 2020.
181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Birchview Capital's 13F filing for Q1 2022, filed 13 May 2022.